Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results...

Area of Science:

• Pediatric Oncology
• Hematology
• Cancer Therapeutics

Background:

• Outcomes for pediatric high-risk acute myeloid leukemia (AML) remain suboptimal.
• The AML-BFM 2004 study investigated strategies to improve prognoses for these patients.

Purpose of the Study:

• To evaluate the efficacy of adding 2-Chloro-2-Deoxyadenosine (2-CDA) to standard consolidation treatment in high-risk AML patients.
• To specifically assess improvements in FAB M4/M5 and MLL rearranged subtypes, which constitute a large portion of high-risk cases.

Main Methods:

• A randomized trial involving 343 children and adolescents with high-risk AML.
• Patients were assigned to receive either standard cytarabine/idarubicine (AI) consolidation or AI plus 2-CDA (6 mg/m²/d on days 1, 3).

Main Results:

• No significant differences in 5-year overall survival (68% vs. 72%) or event-free survival (53% vs. 49%) were observed between the AI/2-CDA and AI arms.
• Cumulative incidence of relapse at 5 years was similar (35% vs. 37%).
• No increased toxicity was noted with the addition of 2-CDA.

Conclusions:

• Moderate-dose 2-CDA during consolidation therapy does not enhance prognosis in pediatric high-risk AML.
• The limited effect may be due to insufficient dosage or the context of a multi-drug regimen, with induction therapy potentially being more critical for 2-CDA efficacy.